A common criticism of Proteomics is the lack of true chemotherapeutics that have resulted from discovery studies. (I hope I don't have to say that I disagree strongly with this point). But I do hear it out there.
A new paper from Henrik Johannson et. al., out of the Karolinksa Institute (Sweden) and just released in Nature Communications describes a new chemotherapeutic target, retinoic acid receptor alpha (RARA) that was discovered almost solely by quantitative proteomics. You can read the paper, open access, here.
Take that, naysayers!
No comments:
Post a Comment